Ultragenyx reports Q3 EPS ($1.40), consensus ($1.45)

Reports Q3 revenue $139.49M, consensus $135.79M. “We continue to see substantial year-over-year revenue growth from our commercial portfolio as we expand geographic access to our medicines. This growth could accelerate with up to three near-term BLA submissions and approvals,” said Emil Kakkis, chief executive officer and president of Ultragenyx (RARE). “Today, we are also sharing an important update from our Phase 3 study in GSDIa with substantially larger reductions in cornstarch intake in crossover patients treated with DTX401. As in our Phase 2 patients, we observed that patients and their physicians were far more comfortable with aggressive titration of cornstarch once they were confirmed to be treated with the gene therapy and had direct access to timely glucose readings.”